RE:RE:A licensing deal would go a long way right nowYour argument makes no sense. Surgical site infections are the most common Healthcare Associate Infectin (HAI) (1) and you are saying that the current practice of using Chloraprep is adequate? Well, the CDC and the Centers for Medicare & Medicaid Services don't agree. The CDC Report referenced above shows a number of new innovations are being tried to control SSIs, including the use of "barriers". Furthermore, Medicare has begun the Hospital Acquired Condition (HAC) Reduction Program to begin penalizing the poorest performing hospitals by reducing their overall reimbursements by 1% for the 25% of the poorest performing hospitals in in rates of:
i.) CLABSIs,
ii.) CAUTIs,
iii.) "serious complications" (including bloodstream infections),
iv.) and next year they'll begin covering surgical site infections after surgery in their analysis as well as C. Diff. and MRSA rates (2).
Covalon has a product in each of these areas and should stand to benefit as hospitals look to improve their practices.
i.) For CLABSIs, Covalon has licensed Mepitel Film IV AM to Molnlycke, who has begun marketing it fairly agressively, making several related presentations at the WOUNDS conference (3).
ii.) For CAUTIs, Covalon has licensed it's silver coated Foley Catheters to Medline, who markets them as their Silvertouch Foley Catheters. Covalon has also recently begun marketing these products under their own brand.
iii.) For bloodstream infections after surgery and control of MRSA, Covalon has their ColActive Plus Ag collagen dressing marketed under their own brand and licensed Smith and Nephew and marketed as BioStep, as well as their SurgiClear product now marketed my Molnlycke as Mepitel Film AM.
As for Covalon's new MiediClear product, I think the paper Molnlycke presented at WOUNDS titled
"An investigation into the ability of an antimicrobial dressing with soft silicone to prevent microbial re-growth" makes a pretty good case for why the dual anti-microbial silicone adhesive offers the best level of protection.....bacteria hang out in hair follicles and can re-emerge shortly after a wipe down with Chloraprep or any chlorahexidine product.
As for your statements about the history here, yes anyone who has done their due dilligence here knows the company has had those past challenges, but I think the change in management and market fundamnetals are going to bring a better future for the company.
You obviously have an agenda here as your only postings on Stockhouse have been to bash Covalon, which you began two years ago when it was trading under 30 cents, but you haven't owned up to the HUGE opportunity you missed on the run to $3. You post history really reeks of that of a disgruntled former employee. I'm a long term investor here, what's your reason for being here?
(1)
CDC SSI Report
(2)
Medicare HAC Reduction Program Overview
(3)
WOUNDS Conference Posters